VERU

VERU is no longer an operating pharma company in any meaningful sense — it sold its only FDA-approved commercial product, the FC2 Female Condom, on December 30, 2024, and management states in the 10-K that it 'currently ha[s] no commercial revenue and may never generate revenue or become profitable.' The revenue line has collapsed from $61.3M in FY2021 to $16.9M in FY2024 (FC2, now divested) to effectively nothing forward. Any P/S multiple (2.9x) is backward-looking noise attached to a business that no longer exists. What remains is a two-asset clinical pipeline — enobosarm and sabizabulin — funded by a shrinking cash pile.

The balance sheet is the disqualifier. The company's own auditor has issued a going-concern explanatory paragraph for FY2025. Cash is $15.8M against operating cash burn of $30.0M per year — roughly six months of runway — while R&D spend rose 22% to $15.6M. Total assets fell 50.6% and equity fell 43.3% year over year; retained deficit is -$317M. The 89% year-over-year drop in share count signals a reverse split, and the filing is explicit that the company 'will need to raise additional capital' and that financing 'may lead to significant dilution.' Near-term, heavily dilutive capital raising is close to certain, and it must happen from a $49M market cap. That is a structurally bad setup for a common-equity holder regardless of the science.